89 related articles for article (PubMed ID: 20631715)
1. Aldosterone, hypertension and heart failure: insights from clinical trials.
Funder JW
Hypertens Res; 2010 Sep; 33(9):872-5. PubMed ID: 20631715
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
[TBL] [Abstract][Full Text] [Related]
4. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
Diercks GF; Overdiek JW; van Veldhuisen DJ
Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Kontush A; Guérin M; Chapman MJ
Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
[TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
8. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
9. RALES, EPHESUS and redox.
Funder JW
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):121-5. PubMed ID: 15860254
[TBL] [Abstract][Full Text] [Related]
10. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
[TBL] [Abstract][Full Text] [Related]
11. Torcetrapib/atorvastatin combination therapy.
Bays H; McKenney J; Davidson M
Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):789-820. PubMed ID: 16181026
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.
Schrier RW; Masoumi A; Elhassan E
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1132-40. PubMed ID: 20448074
[TBL] [Abstract][Full Text] [Related]
13. [Anti-aldosterone therapy in severe heart failure].
van Guldener C; Donker AJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
[TBL] [Abstract][Full Text] [Related]
14. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
[TBL] [Abstract][Full Text] [Related]
15. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
16. [The significance of aldosterone in chronic heart failure: the RALES study].
Simko F; Bada V; Simková M; Simko J; Kovács L; Hulín I
Vnitr Lek; 2002 Aug; 48(8):767-72. PubMed ID: 12425209
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonists in congestive heart failure.
Soberman J; Chafin CC; Weber KT
Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
[TBL] [Abstract][Full Text] [Related]
18. Effect of spironolactone on C-reactive protein levels in patients with heart disease.
Godfrey V; Farquharson CA; Macdonald JE; Yee KM; Struthers AD
Int J Cardiol; 2007 Apr; 117(2):282-4. PubMed ID: 16899309
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone and spironolactone in heart failure.
Weber KT
N Engl J Med; 1999 Sep; 341(10):753-5. PubMed ID: 10471464
[No Abstract] [Full Text] [Related]
20. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
